ArticleJournal of medicinal chemistry2026
Selection of Functional Glycoforms in Anti-SARS-CoV-2 Human IgG1 Monoclonal Antibodies by FcγRIIIa Affinity Chromatography and Mass Spectrometry.
Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monoclonal antibodies activate immune effector cells through Fc-Fcγ receptor interactions, which are strongly influenced by Fc region glycosylation. In this study, three anti-SARS-CoV-2 IgG1 human monoclonal antibodies (hmAbs1-3) derived from the B-cell clones of vaccinated (hmAbs1-2) and convalescent (hmAb3) individuals were investigated, with hmAb3 showing the strongest neutralization activity. Glycoform analysis revealed that hmAb1 predominantly contained ∼60% combined G1F and G2F glycoforms, while hmAb2 consisted of ∼63% G1F, G2F, and G2FS1. In contrast, hmAb3 displayed the greatest glycan diversity with ∼75% comprising G1F, G2F, G2FS1, and G2S1. FcγRIIIa affinity chromatography separated hmAb glycoforms based on receptor affinity, yielding five distinct peaks. Antibody-dependent cellular cytotoxicity (ADCC) assays showed that hmAb3 exhibited the highest activity. Further evaluation of individual hmAb1 fractions collected from the FcγRIIIa affinity column demonstrated a clear correlation between glycosylation patterns and ADCC activity, highlighting the critical roles of Fc galactosylation and sialylation in modulating the effector function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.